USPTO Patent Grants - Organic Chemistry (C07D)

Duk San Neolux Patent Granted, C07D Compound

The USPTO granted Patent US12610737B2 to DUK SAN NEOLUX CO., LTD. on April 21, 2026. The patent covers a compound of Formula 1 classified under C07D 251/24, designed for use in organic electronic elements. The invention aims to improve luminescence efficiency, stability, and lifespan of organic electronic elements.

L'OREAL Patent: C-Glycoside Keratin Treatment

USPTO granted Patent US12606534B2 to L'OREAL covering C-glycoside derivatives for cosmetic treatment of keratin materials including skin whitening, lightening, and depigmenting applications. The patent names Marie-céline Frantz, Maria Dalko, and Alexandre Cavezza as inventors with claims directed to compounds of formula (I) where R is as defined and S* is a mono or polysaccharide. The patent contains 6 claims and covers cosmetic compositions for non-therapeutic skin treatment uses.

Bioactive Phenolate Ionic Complexes, 21 Claims, US12606536B2

The USPTO granted Patent US12606536B2 to Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. for bioactive phenolate ionic complexes. The patent covers isolated materials comprising phenolate species and counter ions in the form of metal salts, phosphonium, or ammonium. Twenty-one claims were allowed.

Process for Preparation of Apalutamide, Synthon B.V., Apr 21

The USPTO granted patent US12606539B2 to Synthon B.V. (a Dutch biopharmaceutical company) for a process to synthesize Apalutamide, along with its solid forms, salts, and solvates, and intermediates used therein. The patent application (18043777) was filed September 3, 2021, and carries 14 claims under CPC classifications C07D 401/04 and C07C 229/48. This grant gives Synthon B.V. exclusionary rights over this synthetic route for the prostate cancer drug.

Daiichi Sankyo SF-1 Antagonist 3-Phenylpropylamine Derivative Patent

The USPTO granted patent US12606533B2 to Daiichi Sankyo Company, Limited for a 3-phenylpropylamine derivative compound exhibiting SF-1 antagonist activity. The patent contains 29 claims and relates to the compound as well as polyfunctional molecules containing the compound moiety, including SF-1 degraders.

INFEX Therapeutics Pyrrole Acid Synthesis Patent Grant

The USPTO granted patent US12606524B2 to INFEX Therapeutics Limited for a novel method of synthesizing pyrrole acid derivatives that function as metallo-β-lactamase inhibitors. These compounds are designed for use in combination with carbapenem antibacterial agents to treat bacterial infections. The patent claims priority to application 18246777, filed October 6, 2021, and contains 3 claims under CPC classification C07D 207/48.

Soochow University Patent: Aniline Acid Anhydride Preparation Method

The USPTO granted Patent US12606530B2 to Soochow University on April 21, 2026, covering an aniline acid anhydride, its preparation method, and a polyaminoacid graft chain. The preparation involves an addition-elimination reaction between N-phenyl amino acid and Boc anhydride under acidic conditions, followed by cyclization under nitrogen to obtain the aniline anhydride. The polyaminoacid graft chain is intended for covalent bonding with fiber materials to improve water-repellent fabric fastness while maintaining wearability.

Helsinn Healthcare SA NK-1 Antagonist Patent Granted Apr 21

USPTO granted Patent US12606527B2 to Helsinn Healthcare SA on April 21, 2026, for crystalline forms of an NK-1 antagonist useful in treating induced vomiting and other disorders. The patent application (18772244) was filed July 14, 2024, and contains 18 claims classified under CPC C07D 213/75 and related pharmaceutical categories.

BASF SE Patent, Oxadiazole Preparation, 19 Claims

The USPTO granted Patent US12606532B2 to BASF SE for a process to prepare substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles. The process involves reacting amidoxime compounds with a haloacetic ester in the presence of a solvent and base. The patent contains 19 claims with inventors Florian Vogt, Kailaskumar Borate, Bernd Wolf, Christopher Koradin, Joachim Gebhardt, Roland Goetz, and Harish Shinde. The application was filed February 1, 2021.

Kumquat Biosciences Heterocycle Patent Granted Apr 21

The USPTO granted patent US12606572B2 to Kumquat Biosciences Inc. on April 21, 2026. The patent covers substituted heterocycle compounds and methods for reducing signaling output of oncogenic proteins. The patent application (19352234) was filed October 7, 2025, and the granted patent contains 20 claims classified under C07D 519/00, A61P 35/00, and A61K 31/553.

Deuterated Organic Compounds and Uses Thereof

The USPTO granted Patent US12606523B2 to Engrail Therapeutics, Inc. covering deuterated organic compounds of Formula I useful for modulating dopamine neurotransmission and treating disorders such as schizophrenia and depression. The patent includes 17 claims encompassing the compounds, processes for their preparation, pharmaceutical compositions, and methods of treatment. Inventors include Krishna Vadodaria, Kimberly Vanover, Jordi Serrats, Vikram Sudarsan, and David Garvey.

Atai Therapeutics US12606525B2 Patent Grant

USPTO granted patent US12606525B2 to Atai Therapeutics, Inc. covering dimethyltryptamine analogues as nitric oxide delivery drugs, specifically compounds of Formula (I) or (II) and pharmaceutical compositions comprising those compounds. The patent was granted on April 21, 2026, with application number 18657306 and 34 claims.

BASF SE Patent - Oxadiazole Synthesis Method

USPTO granted BASF SE patent US12606531B2 on April 21, 2026, covering a process for preparing substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles. The method uses amidoxime compounds reacting with a haloacetic ester in the presence of a base. The patent contains 17 claims with inventors Florian Vogt, Kailaskumar Borate, Bernd Wolf, Christopher Koradin, Roland Goetz, and Harish Shinde.

Biotelliga Holdings Patent US12606569B2 For Loline Alkaloids

USPTO granted Patent US12606569B2 to Biotelliga Holdings Limited on April 21, 2026. The patent covers compositions comprising loline alkaloids and their uses as pesticidal agents, plant growth enhancers, and control agents for insect infection and infestation in plants or animals. The application was originally filed June 15, 2018, with 24 claims.

CHDI Foundation Patent - Deuterated Compounds for Huntingtin Imaging

USPTO granted Patent US12606570B2 to CHDI Foundation, Inc. covering deuterated compounds and imaging agents for detecting huntingtin protein associated with Huntington disease. The patent names seven inventors and contains 8 claims, effective April 21, 2026.

Recurium IP Holdings WEE1 Inhibitor Patent

The USPTO granted Patent US12606567B2 to Recurium IP Holdings, LLC on April 21, 2026, covering salts and forms of WEE1 inhibitor Compound A, including adipate salt Form A. The patent discloses pharmaceutical applications for treating diseases characterized by excessive cellular proliferation, including breast cancer. The patent contains 23 claims under CPC classifications C07D 487/04 and C07B 2200/13.

JAK Inhibitor Compounds, Galderma Holding SA Patent

USPTO granted patent US12606559B2 to Galderma Holding SA on April 21, 2026, covering novel JAK inhibitor compounds of formula (I), methods of synthesis, and methods of using these compounds to treat diseases, conditions, and disorders. The patent contains 14 claims.

ONCO3R B2 Patent - Heterocyclic Compounds and Pharmaceutical Compositions for Disease Treatment

The USPTO granted US Patent 12,606,554 B2 to ONCO3R Therapeutics BV on April 21, 2026. The patent covers heterocyclic compounds according to Formula I and pharmaceutical compositions for treating inflammatory, autoinflammatory, autoimmune, proliferative, fibrotic diseases, transplant rejection, and diseases involving impairment of cartilage or bone turnover, as well as conditions associated with hypersecretion of IL-6, TNFα, interferons, IL-12 and/or IL-23. The patent contains 19 claims and was filed on May 25, 2020.

PPARg Modulators and Methods of Use

USPTO granted Patent US12606541B2 to Eisai R&D Management Co., Ltd. on April 21, 2026. The patent covers 34 claims for PPARg modulators (compounds of Formula 1) and their methods of use, including pharmaceutical compositions containing these compounds. The patent was filed November 8, 2021, with application number 17521666.

Salt of Tetrahydroisoquinoline Derivative, Preparation Method, Medical Use

USPTO granted patent US12606551B2 to Zhejiang Hisun Pharmaceutical Co., Ltd. covering a salt form of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, its preparation method, and pharmaceutical compositions containing it. The patent classifies the compound as an angiotensin II type-2 receptor antagonist. Four claims were allowed.

Anticholinergic Agents Patent US12606549B2, Rezubio Pharma

The USPTO granted US Patent 12606549B2 to Rezubio Pharmaceuticals Co., Ltd covering muscarinic acetylcholine receptor antagonist compounds (including M3 antagonists) and pharmaceutical compositions for treating hyperhidrosis. The patent contains 19 claims and names Yusheng Xiong and Hongping Guan as inventors.

Shenyang Sinochem Agrochemicals - Phenylisoxazoline Compound, US12606547B2

The USPTO granted Patent US12606547B2 to Shenyyang Sinochem Agrochemicals R&D Co., Ltd. covering a synthesis method for a phenylisoxazoline compound. The method uses 2-fluoro-4-chloro-5-methylaniline as a starting material, first synthesizing a uracil ring and then an isooxazoline ring to produce the target compound. The patent contains 8 claims and is classified under CPC C07D 413/10.

Substituted Indole Compounds With Inhibitory Activity for Treating Acute Renal Failure

USPTO granted patent US12606557B2 to the University of Pittsburgh-of the Commonwealth System of Higher Education on April 21, 2026. The patent covers substituted indole compounds and compositions for treating or preventing acute renal failure, as well as infectious diseases and cancer. The application (No. 17927406) was filed on May 27, 2021, with 17 claims and CPC classification C07D 471/04.

TYK2 Inhibitor Compound, BeOne Medicines, US12606556B2

The USPTO granted Patent US12606556B2 to BeOne Medicines I GmbH on April 21, 2026, covering a TYK2 inhibitor compound (Formula I) and its pharmaceutical uses for treating inflammatory or autoimmune diseases. The patent contains 17 claims and classifies under CPC C07D 471/04. Inventors are Qiuwen Wang, Yunhang Guo, and Zhiwei Wang. The patent creates intellectual property rights but does not impose compliance obligations on third parties.

Crystalline Forms of Formula (I) Compounds for Cancer Treatment

The USPTO granted Patent US12606553B2 to Foghorn Therapeutics Inc., covering crystalline forms of a formula (I) compound and compositions containing those forms. The patent also protects methods of using the crystalline forms for treating cancer in subjects, including administration of an effective amount of the compound. The patent, classified under CPC C07D 417/14 (organic chemistry, heterocyclic compounds), contains 11 claims.

Organic Electronic Compound for Organic Electronic Element Patent Granted

The USPTO granted Patent US12606545B2 to DUK SAN NEOLUX CO., LTD. for a compound represented by Formula 1 used in organic electric elements. The invention comprises a first electrode, second electrode, and organic material layer, with applications in electronic devices. The patent claims nine claims covering the compound composition and its use in lowering driving voltage while improving luminous efficiency and lifetime.

MindSet Pharma Indole Derivative Serotonergic Patent Granted

USPTO granted patent US12606543B2 to MindSet Pharma Inc. on April 21, 2026. The patent covers indole derivatives as serotonergic agents useful for activation of serotonin receptors in cells and treating diseases, disorders, or conditions including psychosis, mental illnesses, and CNS disorders.

Memorial Sloan Kettering DCN1-UBC12 Inhibitor Patent Granted

The USPTO granted US Patent 12605373B2 to Memorial Sloan Kettering Cancer Center on April 21, 2026. The patent covers substituted 1-phenyl-3-(piperidin-4-yl)urea analogs as inhibitors of DCN1-UBC12 interaction and DCN1-mediated cullin-RING ligase activity. The application (18596521) was filed March 5, 2024, with 14 claims allowed.

Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation

USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.

Tricyclic KRAS Inhibitor Patent - Incyte Corporation

The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.

Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2

The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.

Evotec Heterocyclic Drug Patent, Apr 14

Evotec Heterocyclic Drug Patent, Apr 14

ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant

The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.

NURIX BTK Degrading Compounds, 36 Claims, Apr 14

The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.

ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2

USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.

Interleukin-17 Inhibitors Patent - Novartis AG

The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.

Washington University Patent for Toxoplasma Gondii Treatment Compounds

The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.

Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method

The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.

Tetracyclic DGK Inhibitor Compounds for Cancer Treatment

USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.

Hoffmann-La Roche Granted Amino-Pyrimidine Amide Patent US12600712B2

USPTO granted Patent US12600712B2 to Hoffmann-La Roche Inc. on April 14, 2026, covering amino-pyrimidine amide compounds with general formula (I) and methods of using such compounds. The patent includes 11 claims and CPC classifications C07D 403/06 and C07D 491/107 in organic chemistry. The filing date was December 7, 2022, with Application No. 18062644.

Gannex Pharma FXR Modulating Compound Patent US12600716B2

USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. on April 14, 2026, for FXR-modulating compounds having a structure of formula (I), including pharmaceutically acceptable salts, esters, and stereoisomers. The patent contains 19 claims and covers therapeutic applications including liver disease (A61P 1/16), metabolic disorders, cardiovascular conditions, and kidney disease.

Boehringer Ingelheim Patent for sGC Activators in Systemic Sclerosis Treatment

The USPTO granted patent US12600715B2 to Boehringer Ingelheim International GmbH covering methods for treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their pharmaceutically acceptable salts. The patent names Mary Ruth Flack, Julia Kaufman, and Indra Sethy-Coraci as inventors and includes 20 claims spanning therapeutic applications including respiratory, dermatological, pain, and immunological indications. This method patent provides Boehringer Ingelheim with enforceable exclusivity over the specified sGC activator treatment protocol for systemic sclerosis in the United States.

Hutchmed Crystalline Forms Patent Grant US12600713B2

USPTO granted patent US12600713B2 to Hutchmed Limited on April 14, 2026 for crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, a pharmaceutical compound. Inventors are Zhenping Wu, Wenji Li, and Yuping Chu. The patent contains 28 claims and was filed on February 27, 2024.

Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof

USPTO granted patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, methods of making the compounds, pharmaceutical compositions, and methods of using the compounds in treating conditions that benefit from somatostatin modulation. The patent includes 4 claims.

MDMA Prodrug Carbamate Compounds - Apoapsis Holdings

USPTO granted Patent US12600708B2 to Apoapsis Holdings, LLC for novel MDMA prodrug carbamate compounds and synthesis methods. The patent covers 19 claims for compounds that are enzymatically cleaved in vivo to produce low-toxicity alcohols. The inventors include Denton W. Hoyer, Robert F. Roscow, Rong Ling, and Chuanjun Gao.

Cannabinoid Derivatives, Precursors and Uses - Patent US12600707B2

USPTO granted patent US12600707B2 to Kare Chemical Technologies Inc. on April 14, 2026, covering new cannabinoid derivatives, precursors, and processes for their preparation. The patent also claims pharmaceutical and analytical uses of these compounds. The patent (10 claims) protects the invention until 2040 based on the September 2020 filing date.

Low-Viscosity Hardener Manufacturing Method Patent

USPTO granted patent US12600706B2 to Nan Ya Plastics Corporation for a method of manufacturing low-viscosity hardener using isomerization of 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride. The patent covers a hardener crude product with a weight ratio of 3:7 to 7:3 between the two anhydrides, producing a final viscosity of 30-50 cps. The patent includes 8 claims and names Te-Chao Liao, Jung-Jen Chuang, Chung-Yu Chen, and Jung-Tsu Wu as inventors.

University of Pittsburgh Heat Shock Protein Modulator Patent for Huntington Disease

USPTO granted patent US12600705B2 to University of Pittsburgh for thiadiazine compounds as heat shock protein modulators. The patent covers therapeutic applications for Huntington disease, other neurodegenerative disorders, and cancer. The patent includes 13 claims.

US12600703B2 - Farnesyl Dibenzodiazepinone Synthesis Patent

USPTO granted patent US12600703B2 to AMO Pharma Ltd. covering methods of synthesizing farnesyl dibenzodiazepinone compounds, including AMO-01. The patent has 4 claims and was filed on May 28, 2021. Patent grants establish legally enforceable intellectual property rights for the disclosed chemical synthesis methods.

Crystalline Forms of Quinazolinyl-Benzonitrile Compound and Ocular Formulations

USPTO granted patent US12600702B2 to Bausch + Lomb Ireland Limited for crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof. The patent covers methods for treating ocular surface pain, dry eye disease, and ocular hyperemia. The application was filed on February 13, 2020 under application number 17430819, with 16 claims granted.